Given today’s declining reimbursement landscape, most health care organizations are engaging in additional cost-saving strategies. The federal 340B Drug Pricing Program is one such opportunity that is available to critical access hospitals (CAHs), disproportionate share hospitals (DSHs), and other eligible covered entities. Whether an entity already participates in the 340B program or is considering it, it’s important to understand the compliance risks and overall program challenges. Here are the top pitfalls to avoid to help ensure a well-run program.
Length: 1 pages (PDF 139 kB)